Alerts
PDF
Other content recommended for you
- Rituximab in neurological disease: principles, evidence and practice
- Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study
- Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders
- Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis
- A practical guide to the treatment of neuromyelitis optica
- Neurodegeneration in multiple sclerosis and neuromyelitis optica
- Novel therapies in CIDP
- Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?